Prominent publications by Jolanta Weglowska

KOL Index score: 20967

BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.

METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were ...

Also Ranks for: Brodalumab Patients |  placebo week |  phase 3 studies |  ustekinumab psoriasis |  monoclonal antibodies

Key People For Week Patients

Top KOLs in the world
Paul *****
rheumatoid arthritis ankylosing spondylitis radiographic progression
Josef ********* ******
rheumatoid arthritis systemic lupus erythematosus radiographic progression
Désirée * * * *** *** ******
rheumatoid arthritis ankylosing spondylitis radiographic progression
Maxime * ********
rheumatoid arthritis ankylosing spondylitis desir cohort
Arthur * *********
psoriatic arthritis celgene corporation week patients
Philip * *****
psoriatic arthritis eli lilly novartis pfizer

Jolanta Weglowska:Expert Impact

Concepts for whichJolanta Weglowskahas direct influence:Week patients,  Brodalumab patients,  Patients brodalumab,  Phase 3 studies,  Placebo week,  Brodalumab placebo,  Plaque psoriasis,  Placebo brodalumab.

Jolanta Weglowska:KOL impact

Concepts related to the work of other authors for whichfor which Jolanta Weglowska has influence:Plaque psoriasis,  Psoriatic arthritis,  Monoclonal antibodies,  Brodalumab patients,  Th17 cells,  Biologic agents,  Atopic dermatitis.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

for the IXORA-PEDS Investigators | Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland